Prevalence, risk factors and treatment outcomes of isoniazid resistant TB in Bulawayo city, Zimbabwe: A cohort study.

Autor:	Manyame-Murwira B; National Tuberculosis Reference Laboratory, Ministry of Health and Child Care, Bulawayo, Zimbabwe. manyamebarbara@yahoo.com., Takarinda KC; AIDS and TB Department, Ministry of Health and Child Care, Harare, Zimbabwe. ktakarinda@theunion.org., Thekkur P; Centre for Operational Research, International Union Against Tuberculosis and Lung Disease, Paris, France. pruthu.tk@theunion.org., Payera B; National Tuberculosis Reference Laboratory, Ministry of Health and Child Care, Bulawayo, Zimbabwe. brightpayera@gmail.com., Mutunzi H; AIDS and TB Department, Ministry of Health and Child Care, Harare, Zimbabwe. hmutunzi@gmail.com., Simbi R; Department of Laboratory Services, Ministry of Health and Child Care, Harare, Zimbabwe. raivasimbi@gmail.com., Siziba N; AIDS and TB Department, Ministry of Health and Child Care, Harare, Zimbabwe. sitwalo@gmail.com., Sibanda E; Department of Health, Bulawayo City Council, Zimbabwe. edmzingwane@gmail.com., Banana C; Department of Health, Bulawayo City Council, Zimbabwe. cbanana@citybyo.co.zw., Muleya N; Department of Environmental Health Services, Ministry of Health and Childcare, Matebeleland South, Zimbabwe. norbertmuleya@gmail.com., Makombe E; Department of laboratory Services, Ministry of Health and Childcare, Midlands Province, Zimbabwe. epmakombe@gmail.com., Jongwe PL; National Tuberculosis Reference Laboratory, Ministry of Health and Child Care, Bulawayo, Zimbabwe. prjongw7@gmail.com., Bhebhe R; National Tuberculosis Reference Laboratory, Ministry of Health and Child Care, Bulawayo, Zimbabwe. bhejane.regina@gmail.com., Mangwanya D; Department of Laboratory Services, Ministry of Health and Child Care, Harare, Zimbabwe. douglas.mangwanya@gmail.com., Dzangare J; AIDS and TB Department, Ministry of Health and Child Care, Harare, Zimbabwe. janet.dzangare@gmail.com., Mudzengerere FH; Family Health International (FHI360), Harare, Zimbabwe. fmudzengerere@gmail.com., Timire C; AIDS and TB Department, Ministry of Health and Child Care, Harare, Zimbabwe. collinstimire2005@yahoo.com., Wekiya E; WHO Supra National Reference Laboratory/National Tuberculosis Reference Laboratory, Uganda. wekiaeric@gmail.com., Sandy C; AIDS and TB Department, Ministry of Health and Child Care, Harare, Zimbabwe. dr.c.sandy@gmail.com.
Jazyk:	angličtina
Zdroj:	Journal of infection in developing countries [J Infect Dev Ctries] 2020 Aug 31; Vol. 14 (8), pp. 893-900. Date of Electronic Publication: 2020 Aug 31.
DOI:	10.3855/jidc.12319
Abstrakt:	Introduction: The isoniazid-resistant TB poses a threat to TB control efforts. Zimbabwe, one of the high TB burden countries, has not explored the burden of isoniazid resistant TB. Hence among all bacteriologically-confirmed TB patients diagnosed in Bulawayo City during March 2017 and December 2018, we aimed to assess the proportion with isoniazid resistant TB and associated factors. Also, we aimed to describe the TB treatment outcomes. Methodology: A cohort study involving routinely collected data by the National TB Reference Laboratory (NTBRL) in Bulawayo City and National TB programme of Zimbabwe. The percentage with 95% confidence interval (CI) was used to express the proportion with isoniazid-resistant TB. The modified Poisson regression was used to assess the association of demographic and clinical characteristics with isoniazid mono-resistant TB. Results: Of 2160 bacteriologically-confirmed TB patients, 1612 (74.6%) had their sputum received at the NTBRL and 743 (46.1%) had culture growth. Among those with culture growth, 34 (4.6%, 95% CI: 3.5-6.7) had isoniazid mono-resistant TB, 25 (3.3%, 95% CI: 2.2-4.9) had MDR-TB. Thus, 59 (7.9%, 95% CI: 6.1-10.1) had isoniazid-resistant TB. Children < 15 years had a higher prevalence of isoniazid mono-resistant TB (aPR= 3.93; 95% CI: 1.24-12.45). Among those with rifampicin sensitive TB, patients with isoniazid-sensitive TB had higher favourable treatment outcomes compared to those with isoniazid-resistant TB (86.3% versus 75.5%, p = 0.039). Conclusions: The prevalence of isoniazid-resistant TB was low compared to neighbouring countries with high burden of TB-HIV. However, Zimbabwe should consider reviewing treatment guidelines for isoniazid mono-resistant TB due to the observed poor treatment outcomes. Competing Interests: No Conflict of Interest is declared (Copyright (c) 2020 Barbara Manyame-Murwira, Kudakwashe Collins Takarinda, Pruthu Thekkur, Bright Payera, Herbert Mutunzi, Raiva Simbi, Nicholas Siziba, Edwin Sibanda, Catherine Banana, Norbert Muleya, Evidence Makombe, Paula Littia Jongwe, Regina Bhebhe, Douglas Mangwanya, Janet Dzangare, Fungai Hamilton Mudzengerere, Collins Timire, Enock Wekiya, Charles Sandy.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu Plný text ve formátu PDF